These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16353079)

  • 1. De novo nodal diffuse large B-cell lymphoma: identification of biologic prognostic factors.
    Abd El-Hameed A
    J Egypt Natl Canc Inst; 2005 Mar; 17(1):20-8. PubMed ID: 16353079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study.
    Hill ME; MacLennan KA; Cunningham DC; Vaughan Hudson B; Burke M; Clarke P; Di Stefano F; Anderson L; Vaughan Hudson G; Mason D; Selby P; Linch DC
    Blood; 1996 Aug; 88(3):1046-51. PubMed ID: 8704213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of BCL-2 gene rearrangements in Argentinean non-Hodgkin lymphoma patients: increased frequency of breakpoints outside of MBR and MCR.
    Noriega MF; De Brasi C; Narbaitz M; Slavutsky I
    Blood Cells Mol Dis; 2004; 32(1):232-9. PubMed ID: 14757440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.
    Gascoyne RD; Adomat SA; Krajewski S; Krajewska M; Horsman DE; Tolcher AW; O'Reilly SE; Hoskins P; Coldman AJ; Reed JC; Connors JM
    Blood; 1997 Jul; 90(1):244-51. PubMed ID: 9207459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
    Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
    World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical expression of CD10 and t(14;18) chromosomal translocation may be indicators of follicle centre cell origin in nodal diffuse large B-cell lymphoma.
    McCluggage WG; Catherwood M; Alexander HD; McBride HA; Smith ME; Morris TC
    Histopathology; 2002 Nov; 41(5):414-20. PubMed ID: 12405909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome.
    Barrans SL; Evans PA; O'Connor SJ; Kendall SJ; Owen RG; Haynes AP; Morgan GJ; Jack AS
    Clin Cancer Res; 2003 Jun; 9(6):2133-9. PubMed ID: 12796378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of t (14; 18) translocation and bcl-2 amplification in diffuse large B-cell lymphoma].
    Jiang HY; Li HL; Hu H; He Y; Zhao T
    Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):84-9. PubMed ID: 17493380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
    Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
    J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD10 antigen expression correlates with the t(14;18)(q32;q21) major breakpoint region in diffuse large B-cell lymphoma.
    Fang JM; Finn WG; Hussong JW; Goolsby CL; Cubbon AR; Variakojis D
    Mod Pathol; 1999 Mar; 12(3):295-300. PubMed ID: 10102615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Survival of patients with primary central nervous system diffuse large B-cell lymphoma: impact of gene aberrations and protein overexpression of bcl-2 and C-MYC, and selection of chemotherapy regimens].
    Yin WJ; Zhu X; Yang HY; Sun WY; Wu MJ
    Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):32-38. PubMed ID: 29325248
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinicopathologic significance of bcl-6 gene rearrangement and expression in three molecular subgroups of diffuse large B-cell lymphoma].
    Xu FP; Liu YH; Luo XL; Zhuang HG; Li L; Luo DL; Xu J; Zhang F; Zhang MH; Du X; Li WY
    Zhonghua Bing Li Xue Za Zhi; 2008 Jun; 37(6):371-6. PubMed ID: 19031715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of the bcl-2 t(14;18) translocation and proto-oncogene expression in primary intraocular lymphoma.
    Wallace DJ; Shen D; Reed GF; Miyanaga M; Mochizuki M; Sen HN; Dahr SS; Buggage RR; Nussenblatt RB; Chan CC
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2750-6. PubMed ID: 16799010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 gene rearrangement in Jordanian follicular and diffuse large B-cell lymphomas.
    Almasri NM; Al-Alami J; Faza M
    Saudi Med J; 2005 Feb; 26(2):251-5. PubMed ID: 15770300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations.
    Niitsu N; Okamoto M; Miura I; Hirano M
    Leukemia; 2009 Apr; 23(4):777-83. PubMed ID: 19151788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
    López-Guillermo A; Cabanillas F; McDonnell TI; McLaughlin P; Smith T; Pugh W; Hagemeister F; Rodríguez MA; Romaguera JE; Younes A; Sarris AH; Preti HA; Lee MS
    Blood; 1999 May; 93(9):3081-7. PubMed ID: 10216105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MBR rearrangement and P-glycoprotein expression are not independent prognostic factors like p53 protein in malignant lymphoma.
    Sun RX; Coste J; Segara C; Rousset T; Fabbro M; Rème T; Legouffe E; Klein B; Rossi JF
    Clin Lab Haematol; 1998 Apr; 20(2):87-94. PubMed ID: 9681218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of bcl-2 gene rearrangement in B-cell Non-Hodgkin's lymphoma.
    Arif A; Jamal S; Mushtaq S; Ahmed S; Mubarik A
    Asian Pac J Cancer Prev; 2009; 10(2):237-40. PubMed ID: 19537891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.